The full guideline for the investigation and management of malignant pleural mesothelioma is published in Thorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.
IntroductIon
The full guideline for the investigation and management of malignant pleural mesothelioma is published in Thorax. 1 The key features of the guideline are highlighted in a short article published to accompany the full guideline. 2 The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.
bAckground The key aim of this guideline is to provide detailed, evidence-based guidance for the investigation of suspected malignant pleural mesothelioma (MPM) and the subsequent care and management of individuals with proven MPM. The main cause of mesothelioma is breathing in asbestos dust-approximately 85% of all male mesotheliomas are attributable to occupational asbestos exposure. Products containing asbestos were banned in the UK in 1999. The latency between first exposure and development of the disease is typically 30-40 years. Only two-thirds of patients in England and Wales receive active anticancer treatment (chemotherapy, radiotherapy and surgery) for MPM and overall median survival is poor at 9.5 months, with 1-year and 3-year survival rates of only 41% and 12%, respectively. The poor survival rates, taken together with the significant variation in treatment and outcomes across the UK, highlight the need for an evidence-based guideline to facilitate the highest standards of care for all patients with mesothelioma in the UK. 3 target audience for the guideline Given the nature of MPM, the majority of the guideline will be relevant to secondary carebased specialists; however, symptom recognition, management and follow-up are all relevant to community-based specialities.
Intended users include primary care general practitioners (GPs) and practice nurses; hospital specialist teams in respiratory medicine, oncology, thoracic surgery and palliative care; hospices/community teams; specialist nurses (including lung cancer and palliative care); radiologists; pathologists.
Areas covered by the guideline include (1) the epidemiology and incidence of mesothelioma in the UK and worldwide, (2) the preferred investigation pathway of suspected cases of MPM, (3) consider special situations including:
• Imaging • Histology/cytology • Frail patient not fit for invasive tests (4) biomarkers, (5) role of mesothelioma MDTs, (6) outline best practice in oncological management, (7) role of chemotherapy, (8) place for radiotherapy, (9) role of surgery, (10) guidance on palliation in MPM, (11) guidance on providing patients with relevant disease-specific information, including medicolegal/compensation issues, (12) summary of future therapeutic agents that might be available within the next 5 years and (13) summary of major MPM recommendations.
Non-pleural mesothelioma is excluded from this guideline.
Methodology
This guideline is based on the best available evidence. The methodology used to write the guideline adheres strictly to the criteria as set considered judgement and grading of evidence The Guideline Development Group (GDG) used evidence tables (see online appendix 2 in the full guideline) 1 to assess the body of evidence for each clinical question. Guideline group members worked in small groups to appraise the literature and at least two members of each group independently appraised each paper using the SIGN critical appraisal checklists. An evidence level was assigned to each relevant study using the SIGN methodology (see table 1) .
From the outset, it was acknowledged that there would be little high-quality evidence for some of the clinical questions. Where this was the case, low-grade evidence was considered, along with expert opinion via consensus at the meetings of the GDG. Parameters were set by the GDG when appraising the evidence:
• How applicable the obtained evidence was in making recommendations for the defined target audience.
• Whether the evidence was generalisable and relevant to the target population.
• Whether there was a clear consistency in the evidence used to support recommendations.
• What the implications would be on clinical practice in terms of resources and skilled expertise.
Cost-effectiveness was not considered in detail as in-depth economic analysis of recommendations falls outside of the British Thoracic Society (BTS) guideline production process. However, the GDG were asked to be mindful of any barriers to implementing the recommendations and GPPs.
Recommendations were graded A to D as indicated in table 2.
In line with SIGN guidance, 'minus' evidence was considered where necessary, but only in such instances when there were no published 'plus' papers. In this context, any recommendation based on this evidence was made Grade D. GPPs were included where research evidence was lacking, as the GDG felt it was important to highlight practical points that could improve the care of patients. Research recommendations were also highlighted. Extrapolated evidence from studies rated as 2+ √ Important practical points for which there is no research evidence, nor is there likely to be any research evidence. The guideline committee wishes to emphasise these as Good Practice Points. 
Research recommendation
The role of VATS-PP and EPD in good prognosis patients should be examined further in clinical trials, which should include robust measurement of quality of life. Good practice points ✔ All mesothelioma cases should be discussed in a timely fashion by a MDT that reviews a sufficient number of cases to maintain expertise and competence in the diagnosis and treatment of MPM.
Open Access ✔ The MDT membership should fulfil the requirements set by national cancer peer review (to include a named clinical nurse specialist for MPM). ✔ The MDT should maintain an up-to-date portfolio of mesothelioma trials and offer recruitment to all eligible patients. ✔ A personalised care approach should be considered for each patient. Patients should be offered 3-4 monthly follow-up appointments with an oncologist, respiratory physician or specialist nurse according to their current treatment plan. If patients wish to be seen less frequently, offer regular telephone follow-up with specialist nurse with an option to attend clinic in the event of clinical deterioration.
Healthcare providers need to use clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply recommendations for the management of patients. The recommendations presented here are a guide and may not be appropriate for use in all situations. The guidance provided does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.
